ClinicalTrials.gg

Program

libevitug

Also written as “HH-003(20mg/kg)”, “HH-003(10mg/kg)” and “Libevitug 20 mg/kg”.

Its studies are mostly in Hepatitis D · Hepatitis B, Chronic, led by Huahui Health.

Furthest: phase 3, since Mar 24, 20266 company-led studies, 1 open or runningNext primary completion: Sep 12, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huahui Health61 open or runningphase 3since Mar 24, 2026Sep 11, 2022Sep 12, 2028phase 3 · NCT07499544

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2022First study: phase 1 study in Chronic HBV InfectionFirst studyNCT05542979 · 68 enrolled · China
  2. Dec 30, 2022Phase 2 study in Hepatitis B, ChronicNCT05674448 · 9 enrolled · China
  3. Feb 9, 2023Phase 2 study in Chronic HBV InfectionNCT05734807 · 74 enrolled · China
  4. Apr 20, 2023Phase 2 study in Hepatitis B, ChronicNCT05839639 · 73 enrolled · China
  5. May 7, 2023Phase 2 study in Chronic Hepatitis Delta Virus InfectionNCT05861674 · 101 enrolled · China, Pakistan
  6. Mar 24, 2026Phase 3 study in Hepatitis DPhase 3 reachedNCT07499544 · 160 planned · United States, China, Pakistan

Ahead

  1. Sep 12, 2028Primary completion: phase 3 study in Hepatitis DNCT07499544

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07499544Hepatitis D · United States, China, Pakistan3RecruitingSep 12, 2028160
NCT05861674Chronic Hepatitis Delta Virus Infection · China, Pakistan2CompletedJul 18, 2024101
NCT05839639Hepatitis B, Chronic · China2CompletedDec 5, 202273
NCT05734807Chronic HBV Infection · China2CompletedApr 17, 202474
NCT05674448Hepatitis B, Chronic · China2TerminatedJul 25, 20229
NCT05542979Chronic HBV Infection · China1CompletedMar 15, 202268

How it is read

Names in the registry

  • “HH-003(20mg/kg)”, 1 entry
  • “HH-003(10mg/kg)”, 1 entry
  • “Libevitug 20 mg/kg”, 1 entry
  • “Libevitug 10 mg/kg”, 1 entry
  • “HH-003 and NrtIs”, 1 entry

Codes read as this program: HH003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.